United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC lessened its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 6.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 27,123 shares of the biotechnology company’s stock after selling 1,960 shares during the quarter. Brandywine Global Investment Management LLC owned about 0.06% of United Therapeutics worth $9,570,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Milestone Asset Management LLC boosted its stake in United Therapeutics by 56.5% during the fourth quarter. Milestone Asset Management LLC now owns 2,874 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 1,037 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in shares of United Therapeutics by 9.1% during the 4th quarter. Janney Montgomery Scott LLC now owns 9,427 shares of the biotechnology company’s stock valued at $3,326,000 after purchasing an additional 789 shares in the last quarter. Korea Investment CORP grew its stake in shares of United Therapeutics by 6.2% in the 4th quarter. Korea Investment CORP now owns 39,289 shares of the biotechnology company’s stock worth $13,863,000 after purchasing an additional 2,300 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of United Therapeutics by 35.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 192,546 shares of the biotechnology company’s stock worth $68,999,000 after purchasing an additional 50,291 shares in the last quarter. Finally, Burney Co. lifted its stake in United Therapeutics by 113.3% during the fourth quarter. Burney Co. now owns 23,922 shares of the biotechnology company’s stock valued at $8,441,000 after purchasing an additional 12,705 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $364.91, for a total value of $3,649,100.00. Following the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $940,373.07. The trade was a 79.51 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the firm’s stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the transaction, the director now directly owns 8,480 shares of the company’s stock, valued at $2,703,424. The trade was a 22.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 72,500 shares of company stock worth $26,134,500. 11.90% of the stock is currently owned by company insiders.

United Therapeutics Stock Performance

United Therapeutics stock opened at $308.27 on Tuesday. The business’s 50-day simple moving average is $339.04 and its 200-day simple moving average is $355.62. United Therapeutics Co. has a 52 week low of $221.53 and a 52 week high of $417.82. The firm has a market capitalization of $13.85 billion, a PE ratio of 13.54, a PEG ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, beating the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analysts’ expectations of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the prior year, the business earned $4.36 earnings per share. Research analysts forecast that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on UTHR. HC Wainwright reaffirmed a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. UBS Group upped their target price on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. Finally, StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.